 "MSCI sets aside Piramal Pharma's exclusion from global standard index")
Global index provider Morgan Stanley Capital International (MSCI) has set aside the excision of Piramal Pharma Solutions (Piramal Pharma) from its Global Standard Index after the stock hit the lower trading limit.
Shares of Piramal Pharma dropped 5 per cent to close at Rs 163.3 on the BSE. The stock has hit a lower trading limit in three of the five trading sessions since its listing.
The removal from the MSCI index is likely to result in selling by passive trackers to the tune of $50 million, according to Nuvama Alternative & Quant Research.
“Since Piramal Pharma is trading at lower circuit, MSCI index has yet again deferred its exclusion from the MSCI Global Standard Index by two trading days. Earlier, Piramal Pharma was going to be excluded on October 20 and then on October 27,” said a note by Nuvama.
The company was listed separately on October 19, following its demerger from Piramal Enterprises.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%